Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report specifically addresses a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding director share allocations rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The only change noted is an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan due to a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on August 16, 2013.
- Share Price: The transaction was valued at $51.63 per ADS.
- Beneficiaries: The allocation involved Dr. M. Slaoui (Director/PDMR) and Dr. K. Slaoui (Connected Person).
- Volume: The total number of ADSs allocated was 4.
- Plan Context: The shares are notionally held within the GSK 401K plan.